Aernoud Fiolet

301 Predictors of early intolerance to low-dose colchicine in patients with coronary disease Figure 4: Univariable and multivariable associations with intolerance due to myalgia. Crude OR Adjusted OR Predictors OR 95% confidence interval P Value OR 95% confidence interval P Value Forrest plot Female sex 1.20 (0.61 to 2.19) 0.579 1.27 (0.64 to 2.33) 0.462 Age above 70 years 1.44 (0.84 to 2.40) 0.173 1.35 (0.77 to 2.31) 0.286 Non caucasian race NA NA NA Active smoker 0.95 (0.43 to 1.84) 0.879 Obesity 1.24 (0.69 to 2.39) 0.500 1.30 (0.72 to 2.51) 0.410 Hypertension 1.05 (0.63 to 1.75) 0.840 Diabetes 1.02 (0.5 to 1.90) 0.950 Diabetes on insulin 0.62 (0.1 to 1.99) 0.502 eGFR < 60 ml/min/1.73m2 0.94 (0.33 to 2.14) 0.895 0.80 (0.27 to 1.86) 0.641 History of myocardial infarction 0.88 (0.53 to 1.48) 0.632 History of LVEF < 50% 1.31 (0.57 to 2.62) 0.482 History of atrial fibrillation 1.89 (0.98 to 3.41) 0.044 2.46 (0.78 to 6.95) 0.113 Anticoagulant use 1.47 (0.74 to 2.68) 0.238 0.68 (0.22 to 2.06) 0.501 Beta-blocker use 0.80 (0.48 to 1.37) 0.411 Calcium-channel blocker 1.20 (0.64 to 2.11) 0.544 Renin angiotensin inhibitor use 0.81 (0.48 to 1.41) 0.443 High-dose statin use 0.99 (0.60 to 1.66) 0.980 1.08 (0.65 to 1.81) 0.767 Very high-dose statin use 0.49 (0.19 to 1.06) 0.101 Ezetimibe use 0.50 (0.22 to 0.99) 0.065 0.50 (0.22 to 1.00) 0.070 Figure 4: Univariable and multivariable associations with intolerance due to myalgia to low-dose colchicine. Sex, age above 70 years, obesity, eGFR < 60 ml/min/1.73m2, history of atrial fibrillation, anticoagulatn use, high dose statin use and exetemibe were were entered in the multivariable model. Abbrevations: eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NA, not apllicable; OR, odds ratio Figure 4: Univariable and multivariable associations with intolerance due to myalgia to low-dose colchicine. A maximum of 1 predictor per 10 outcome events was were entered in the multivariable model, chosen on clinical relevance: Sex, age above 70 years, obesity, eGFR < 60 ml/min/1.73m 2 , history of atrial fibrillation, anticoagulatn use, high dose statin use and exetemibe. Abbrevations: eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NA, not applicable; OR, odds ratio Statins and intolerance Statin dose was inversely related to intolerance due to any perceived side effect, with intolerance in 5.7% participants using atorvastatin dose equivalent 80mg versus 8.4% for those treated with lower dosed statins (odds ratio, 0.66; 95% confidence interval 0.477 to 0.92, p = 0.016) (Figure 2) . In patients that were treated with statins, atorvastatin (45.6%) and simvastatin (25.2%) were used most often. Other statins used were rosuvastatin (23.9%), pravastatin (3.8%) and fluvastatin (0.53%). In univariable analysis, simvastatin was associated with a lower odds for intolerance due to any perceived side effects as compared to any other statin (odds ratio 0.74; 95% confidence interval 0.55 to 0.99) (Figure 5a) None of the statins were associated with an increased risk for intolerance due to gastro-intestinal tolerance. However, odds for intolerance due to myalgia were significantly higher in patients using rosuvastatin (odds ratio 3.26, 95% confidence interval 1.93 to 5.50, p < 0.001) and lower in patients using simvastatin (odds ratio 0.34, 95% confidence interval 1.13 to 0.73, p = 0.012) when compared to any other statin.